Category: Clinical trials

Roche and Genentech start MANOEUVRE – an new global phase 2 study of GYM329

October 4, 2022 By Bine Haase

MANOEUVRE: a new global Phase 2 study to begin by the end of the yearMANOEUVRE is a new global Phase 2 clinical study that aims to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics and efficacy of GYM329 (RO7204239), an investigational anti-myostatin antibody targeting muscle growth, in individuals living with FSHD.As there are currently no approved treatments […]

Clinical trials News

Fulcrum Therapeutics® Announces Phase 3 Clinical Trial of Losmapimo (REACH)

March 3, 2022 By Bine Haase

https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeuticsr-announces-reach-phase-3-clinical-trial/?fbclid=IwAR2WpAYsthlB2it094PMDEGP9b671YY5pKh7vQSgU10IEc5vxzHqMIu5rj4

Clinical trials News Recent research

A “patient friendly” summary by FSHD Society on the results of Fulcrums phase 2b study on Losmapimod

June 24, 2021 By Bine Haase

Clinical trials News Recent research

Fulcrum announces results from ReDUX4 Trial with Losmapimod in FSHD

June 24, 2021 By Bine Haase

Clinical trials News

UK FSHD patient registry publishes overview of ongoing clinical trials

March 11, 2021 By Bine Haase

Ben Porter, curator of the UK FSHD Patient Registry, has published a visual overview of ongoing clinical trials for FSHD (type 1 and 2) worldwide. In addition to the already known Fulcrum Therapeutics trial, which is in clinical phase 2 and whose first results are expected in the middle of the year, you will also […]

Clinical trials

An update on the impact of COVID-19 on the Fulcrum clinical trials

April 8, 2020 By Bine Haase